Sierra Oncology (SRRA) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Environmental Extreme Weather Intensity Materials Nature Offset Package Packaging Pandemic Raw Materials Toxic Water Access Benefits Black California Consumer Privacy Act Collective Bargaining Community Culture Customer Cybersecurity Data Privacy Data Security Death Disability Diversity Drug Pricing Employee Engagement General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Human Capital Human Resources Incident Injuries Injury Privacy Product Quality Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Social Society Supplier Supply Chain Talent Training Union Volunteer Workers Workforce Activist Anti-corruption Antitrust Assessment Assurance Attorney General Attorneys General Audit Bribery Chronic Class Action Lawsuit Classified Classified Board Commitment Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversight Poison Pill Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

DFAN14A

SRRA Sierra Oncology Inc

13 Apr 22

Additional proxy materials by non-management

5:16pm

Vote support at last AGM

Sierra Oncology, Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 8, 2021. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.
Proposal 1: Election of three Class III Directors

Name of Director

Stephen G. Dilly, M.B.B.S., Ph.D.	7,383,406	184,914	3,349,095
Robert Pelzer	7,364,490	203,830	3,349,095
Josh Richardson, M.D.	7,383,296	185,024	3,349,095

Each director nominee was duly elected to serve until the 2024 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm


For	Against	Abstain
10,841,357	72,137	3,922

The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
Proposal 3: Approve the advisory resolution on the compensation of the Company’s named executive officers

For		Against		Abstain		Broker Non-Votes

7,530,150		32,247		5,923		3,349,095

The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.
Proposal 4: Approve the frequency of future advisory votes on the compensation of the Company’s named executive officers


Every 1 year	Every 2 Years	Every 3 Years	Abstain	Broker Non-Votes
7,095,125	2,650	465,898	4,647	3,349,095

The stockholders approved, on an advisory basis, to hold the advisory vote on future named executive compensation every one year. Based on the results of the vote, and consistent with the recommendation of the Company’s Board of Directors (the “Board”), the Board has determined to hold a non-binding advisory vote regarding named executive officer compensation every one year until the next required non-binding advisory vote on the frequency of holding future votes regarding named executive officer compensation.